Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 5/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 3/20 | 0.30 |
| ▸ | JAK1 | P23458 | 3/20 | 0.30 |
| ▸ | JAK3 | P52333 | 3/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31593420 | 1.00 | TYK2 (0.31) | TYK2KDM4EALDH1A1JAK2JAK1 | |
| SCHEMBL31593508 | 0.92 | BACE1 (0.31) | TYK2 | |
| SCHEMBL31593489 | 0.92 | BACE1 (0.31) | TYK2 | |
| SCHEMBL31593509 | 0.84 | KDM4E (0.33) | KDM4EALDH1A1 | |
| SCHEMBL31593564 | 0.84 | GRM4 (0.32) | ALDH1A1 | |
| SCHEMBL31593681 | 0.83 | SMN1; SMN2 (0.34) | ALDH1A1 | |
| SCHEMBL31593662 | 0.82 | WNT1 (0.35) | KDM4EALDH1A1 | |
| SCHEMBL31593481 | 0.82 | SMN1; SMN2 (0.39) | ALDH1A1 | |
| SCHEMBL31593460 | 0.81 | KDM4E (0.33) | KDM4EALDH1A1 | |
| SCHEMBL31593559 | 0.80 | DGAT1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171430-A1 | PYRAZOLYL COMPOUNDS AS KV7 CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD (US) | 2025-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171430-A1 | PYRAZOLYL COMPOUNDS AS KV7 CHANNEL ACTIVATORS | KCNA7, KCNK17, KCNT1 | TYK2 3835/4885KDM4E 1571/4885ALDH1A1 3403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.